Cr | Istock | Getty images
A version of this article appeared for the first time in the Healthy Bulletin returns from CNBC, which brings the latest medical care news directly to its entrance tray. Subscribe here To receive future editions.
Another potential competitor for the great success of obesity of Eli Lilly and Novo Nordisk I just show positive data, but this time, it is from China.
An experimental weekly injection developed by the Chinese medication manufacturer Hengurui Pharma and its partner of the United States, Kailera Therapeutics, succeeded in a late trial in China in China, which put medication manufacturers on its way to seeking approval there.
Kailera is among several companies, such as Merck, Novo Nordisk and Regeneron, who have taken advantage of the Chinese market in search of a drug that could win a portion of the Board of Drug Market for Weight. In May 2024, Kailera authorized the rights outside the region of Gran China to multiple experimental medications of Hengurui in exchange for more than $ 100 million in advanced payments and a short term, a capital participation of 20% and almost $ 6 billion in future milestones.
This is how the medicine, called HRS9531, served in the trial: it helped patients lose almost 18% of their body weight on average after 48 weeks, which is more than 16% higher weight loss than those of a placebo saw.
Almost 9 out of 10 people who received injection lost at least 5% of their body weight, and 44.4% of patients achieved at least 20% weight loss, according to a statement from companies. There was no plateau in weight loss at 48 weeks.
The companies did not reveal specific security data or how well the patients tolerated the medication, only saying that these results were consistent with the previous data on treatment and other LPG-1. Most adverse injection events were related to gastrointestinal and mild to moderate in gravity, companies said.
HENGRUI will submit a request for approval for the medicine in China. Meanwhile, Kailera will begin global studies that use higher doses and keep patients in the treatment for a longer time, said the startup CEO, Ron Renaud, in the statement.
It is likely that it will still pass several years before HRS9531 enter the market, particularly in the United States and other nations outside China. But the results of the medication seem promising, and positioning it as a potential competitor for the weekly injection of weight loss of Eli Lilly Zepbound.
Both drugs work activating two hormones naturally produced in the body: peptide 1 similar to glucagon, known as LPG-1 and insulinotropic polypeptide dependent on glucose, or GIP. It is said that the combination slows the emptying of the stomach, which makes people feel full for longer and suppress the appetite by slowing the signs of hunger in the brain.
In two phase tests three that register approximately 3,000 adults with obesity or type 2 diabetes, Zepbound helped patients lose an average of up to 21% of their body weight for 72 weeks.
It is difficult to directly compare the results of different clinical trials, especially because the latest results in HRS9531 were only more than 500 patients. But the medicine still achieved significant weight loss for 48 weeks, which increases hopes about its potential for a longer period of time.
Meanwhile, Novo Nordisk's weekly injection is only aimed at LPG-1.
Do not hesitate to send any advice, suggestion, stories ideas and data to Annika in [email protected].
The latest in Medical Care Technology: The non -profit organization of the Co -founder of 23Andme Wojcicki acquires a genetic test company
Anne Wojcicki, co -founder and executive director of 23Andme Inc., during the South By Southwest (SXSW) festival in Austin, Texas, USA, on Friday, March 10, 2023.
Jordan Vonderhaar | Bloomberg | Getty images
Well, friends, after a long saga, Anne Wojcicki has officially recovered the control of the GENETICS TEST COMPANY 23Andme.
Wojcicki co -founded 23 Andme and served as CEO until the company requested bankruptcy protection of chapter 11 in March. His new nonprofit organization, Tam Research Institute, has completed his acquisition of the commercial lines of services and research services of the 23Andme personal genome, the company announced on Monday.
“As part of Tam, 23Andme continues to operate and provide customer DNA research and test services,” said the company in a statement. “TTAM undertakes to provide customers with options and transparency with their data, including the option to change their decision on whether to participate in the investigation.”
Tam is an acronym for the first 23Andme letters, according to the Wall Street Journal.
23Andme shot in the mainstream with DNA test kits in the home that gave customers an idea of their family stories and genetic profiles. But the five -time company CNB Disruptor 50 struggled to generate recurrent income and defend the viable research and therapeutic companies after going over.
When it became clear that 23Andme's finances were unstable, Wojcicki presented several proposals to take the company in private while she was still its executive director. These plans were not successful, and finally had to compete against other possible buyers in a bankruptcy auction.
And, of course, there were some unexpected turns.
In May, Regeneron Pharmaceuticals announced that it would buy most of the 23Andme assets for $ 256 million after it came out at the top during the bankruptcy auction. But Wojcicki presented a separate offer of $ 305 million through TTAM and pressed to reopen the auction.
A month later, he did exactly that, and Tam announced that he had successfully surpassed Regeneron.
“I am delighted that the Tam Research Institute can continue the 23Andme mission to help people access, understand and benefit from the human genome,” Wojcicki said in a June statement.
Do not hesitate to send any advice, suggestion, stories ideas and data to Ashley at [email protected].
